Mersana Therapeutics Inc
NASDAQ:MRSN

Watchlist Manager
Mersana Therapeutics Inc Logo
Mersana Therapeutics Inc
NASDAQ:MRSN
Watchlist
Price: 28.65 USD -0.28%
Market Cap: 143.3m USD

Intrinsic Value

The intrinsic value of one MRSN stock under the Base Case scenario is 10.98 USD. Compared to the current market price of 28.65 USD, Mersana Therapeutics Inc is Overvalued by 62%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MRSN Intrinsic Value
10.98 USD
Overvaluation 62%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Mersana Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about MRSN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is MRSN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Mersana Therapeutics Inc.

Explain Valuation
Compare MRSN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about MRSN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Mersana Therapeutics Inc

Current Assets 60m
Cash & Short-Term Investments 56.4m
Receivables 168k
Other Current Assets 3.4m
Non-Current Assets 2.7m
PP&E 2.2m
Other Non-Current Assets 500k
Current Liabilities 43.3m
Accounts Payable 2.4m
Accrued Liabilities 17.1m
Other Current Liabilities 23.8m
Non-Current Liabilities 79m
Other Non-Current Liabilities 79m
Efficiency

Free Cash Flow Analysis
Mersana Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Mersana Therapeutics Inc

Revenue
33.2m USD
Operating Expenses
-100.6m USD
Operating Income
-67.4m USD
Other Expenses
-2.7m USD
Net Income
-70.1m USD
Fundamental Scores

MRSN Profitability Score
Profitability Due Diligence

Mersana Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROE
ROE is Increasing
Operating Margin is Increasing
38/100
Profitability
Score

Mersana Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

MRSN Solvency Score
Solvency Due Diligence

Mersana Therapeutics Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
33/100
Solvency
Score

Mersana Therapeutics Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MRSN Price Targets Summary
Mersana Therapeutics Inc

Wall Street analysts forecast MRSN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRSN is 33.86 USD with a low forecast of 27.52 USD and a high forecast of 52.5 USD.

Lowest
Price Target
27.52 USD
4% Downside
Average
Price Target
33.86 USD
18% Upside
Highest
Price Target
52.5 USD
83% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Mersana Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MRSN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

MRSN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one MRSN stock?

The intrinsic value of one MRSN stock under the Base Case scenario is 10.98 USD.

Is MRSN stock undervalued or overvalued?

Compared to the current market price of 28.65 USD, Mersana Therapeutics Inc is Overvalued by 62%.

Back to Top